T1	MajorClaim 1 89	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
T2	Premise 1297 1521	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).
T3	Premise 1522 1663	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
T4	Premise 1664 1811	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
T5	Claim 1812 1956	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
R1	Support Arg1:T3 Arg2:T5	
R2	Support Arg1:T4 Arg2:T5	
R3	Support Arg1:T2 Arg2:T5	
